Pressure point: blood flow restriction exercise and the pain paradox in musculoskeletal injury and persistent pain populations—a narrative review - Takeaways - MDSpire

Pressure point: blood flow restriction exercise and the pain paradox in musculoskeletal injury and persistent pain populations—a narrative review

  • By

  • Luke Gray

  • Luke Hughes

  • Lynn Kelly

  • Robert Barker-Davies

  • Russell Coppack

  • Nick Caplan

  • Robyn Cassidy

  • Sarah Lewis

  • Alexander Bennett

  • Peter Ladlow

  • June 16, 2026

  • 0 min

Share

  • 1

    Blood flow restriction (BFR) exercise can reduce pain and enhance muscular strength at lower intensities, making it valuable for musculoskeletal injury rehabilitation.

  • 2

    Higher occlusive pressures during BFR exercise may lead to hyperalgesia, especially in individuals with persistent pain due to altered pain modulation.

  • 3

    BFR exercise's effects on pain modulation are complex, involving metabolic, vascular, neurological, and psychological pathways.

  • 4

    Psychological factors like catastrophising can exacerbate pain responses, highlighting the need for individualized BFR exercise prescriptions.

  • 5

    Careful monitoring and pressure selection in BFR exercise are essential to maximize analgesic benefits while minimizing adverse pain responses.

Original Source(s)

Pressure point: blood flow restriction exercise and the pain paradox in musculoskeletal injury and persistent pain populations—a narrative review

  • by Luke Gray, Luke Hughes, Lynn Kelly, Robert Barker-Davies, Russell Coppack, Nick Caplan, Robyn Cassidy, Sarah Lewis, Alexander Bennett, Peter Ladlow

  • June 16, 2026

Related Content

AI Scribes Lag Clinicians on Note Quality

A VHA study across 11 vendors finds AI-generated primary care notes score lower than clinician-written notes, with the largest deficits in thoroughness, organization, and usefulness

Preoperative oral spicy stimulation for postoperative pain reduction after spinal surgery: a randomized controlled trial

Retatrutide Shows 28% Weight Loss in Phase 3 Trial

Nearly half of participants receiving the highest dose achieved at least 30% body weight reduction.